EFFECT ·Filed Apr 20, 2026

LGVN

Longeveron Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed5mo ago SEC9999999995-26-001244
IPO/offering going effective
Actionable Insight ▼ Bearish

Traders should anticipate increased selling pressure as stockholders may begin distributing shares immediately. Monitor volume and price action closely for signs of distribution. Given the company's weak cash position and small market cap, even moderate selling could drive material downside.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
LGVN ▼ -38.91% at T+60d
SHORT call ✓ call won +38.91% · α vs SPY +45.69% · entry $1.04 → $0.6353
Entry anchored
Apr 17, 03:59 PM ET
via exchange tick
T+1d
-1.92%
call +1.92% · α +1.27%
$1.02
settled 5mo ago
T+5d
-13.46%
call +13.46% · α +14.37%
$0.9000
settled 5mo ago
T+20d
-35.00%
call +35.00% · α +39.20%
$0.6760
settled 5mo ago
T+60d
-38.91%
call +38.91% · α +45.69%
$0.6353
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Longeveron Inc. (LGVN) has announced the effectiveness of its S-1 registration, allowing 30.9 million shares to be resold by selling stockholders. This is not an IPO raising capital for the company but a resale registration that increases float and creates immediate dilution overhang, particularly concerning given the company's small $26M market cap and prior going concern risks.

Key Facts

  • S-1 registration has become effective as of April 17, 2026
  • Registration covers resale of 30.9 million shares by existing stockholders, not a capital raise for the company
  • Shares include those from recent private placements and convertible preferred stock conversions
  • Company has a $26M market cap, making the registered volume highly dilutive
  • Longeveron is a clinical-stage biotech with going concern risks and Nasdaq compliance issues

Financial Impact

Up to 30.9 million shares now eligible for public resale, representing significant potential dilution; no proceeds to company

dilutionfloatliquidityshare price

Risk Factors

  • Immediate share price pressure from stockholder sales
  • Further dilution if company needs to raise additional capital
  • Nasdaq delisting risk if share price falls below $1 minimum bid requirement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001244
Document: 9999999995-26-001244-index.html9999999995-26-001244
Document: 9999999995-26-001244.txt9999999995-26-001244
12 reports for LGVN
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +42.59%Apr 10, 2026
Filters
Rows
Reports for LGVN — sortable, filterable
TypeNow
Sep 14, 2026
17d ago
8-K
BULLISH ★ 5/10
$6.86 $2.49▼ −63.70%▼ −64.52%$2.57 (−62.61%)
Jul 13, 2026
11w ago
3
NEUTRAL ★ 2/10
$0.6223 $0.6022▼ −3.23%▼ −1.93%$2.57 (+312.18%)
Jun 5, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$0.7540 $0.7900▲ +4.77%▲ +2.66%$2.57 (+240.19%)
May 20, 2026
19w ago
Press Release
NEUTRAL ★ 4/10
$0.7210 $0.8150▲ +13.04%▲ +11.44%$2.57 (+255.76%)
May 13, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$0.7030 $0.7210▲ +2.56%▲ +3.28%$2.57 (+264.86%)
May 8, 2026
20w ago
8-K
BEARISH ★ 7/10
$0.8380 $0.6760▲ +19.33%▲ +19.25%$2.57 (−206.09%)
Apr 20, 2026
23w ago
EFFECT
BEARISH ★ 6/10
$1.04 $0.9000▲ +13.46%▲ +14.37%$2.57 (−146.63%)
Apr 10, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$1.12 $1.04▼ −7.14%▼ −10.44%$2.57 (+129.02%)
Apr 10, 2026
24w ago
S-1
BEARISH ★ 6/10
$1.12 $1.04▲ +7.14%▲ +10.44%$2.57 (−129.02%)
Mar 17, 2026
28w ago
Press Release
BEARISH ★ 7/10
$0.9760 $0.9730▲ +0.31%▼ −0.41%$2.57 (−162.81%)
Showing 10 of 12

US Market Status

Market Open — Closes in 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access